Volume 19, Issue 77 (6-2011)                   J Adv Med Biomed Res 2011, 19(77): 53-61 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Sharifi yazdi M K, Azarsa M, Shirazi M H, Rastegar Lari A, Owlia P, fallah Mehrabadi J, et al . The Frequency of Extended Spectrum Beta Lactamase and CTX M-I of Escherichia Coli Isolated from the Urine Tract Infection of Patients by Phenotypic and PCR Methods in the City of Khoy in Iran. J Adv Med Biomed Res 2011; 19 (77) :53-61
URL: http://journal.zums.ac.ir/article-1-1657-en.html
1- Dept. of Laboratory, Faculty Paramedical Sciences, Tehran University of Medical Sciences. Tehran, Iran
2- Devision of Microbiology, Dept. of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
3- Antimicrobial Resistant Research Center, Tehran University of Medical Sciences, Tehran Iran
4- Dept. of Medical Microbiology, Faculty of Medicine, Shahed University, Tehran, Iran
5- Dept. of Medical Microbiology, Faculty of Medicine, Shahed University, Tehran, Iran .
6- MARS Bioinformatics Institute, Tehran, Iran.
7- Dept. of Microbiology, Faculty of Medicine, Tabriz University of Medical Sciences, International Units(ARAS), Iran
8- Devision of Microbiology, Dept. of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. , soltanirad34@yahoo.com
Abstract:   (174196 Views)

Background and Objective: The production of Extended Spectrum Beta Lactamases (ESBLs) by Escherichia coli is the main cause of resistance to Cephalosporins.  In the past decade, CTX-M enzymes have become the most prevalent ESBLs in Europe, Canada, and Asia.  In this study, the frequency of ESBL-producing E.coli and molecular detection of the CTX-M-I group was investigated.
Materials and Methods: A total of 400 urine samples were collected from both hospitalized and out-patients in Khoy’s hospitals between November 2009 and April 2010.  Out of these samples, 188 were identified as  E.coli  by standard biochemical tests. The antibiotic Susceptibility tests to 10 antibiotics were performed by the-disk-agar diffusion (DAD) method. ESBL production was screened by phenotypic test that including disk diffusion agar and combined disk as recommended by the Clinical and Laboratory Standards Institute (CLSI). Screened isolates were investigated by PCR assay for detection of CTX-M-I group genes.
Results: The results show that out of 188 E.coli isolates identified, 56 (29.8%) were producing ESBls by phenotypic test. All isolates were sensitive to imipenem. Overall, 49 (87.5%) isolates were confirmed as CTX-M-I producer by PCR.
Conclusion: The results of this study showed that about 30% of the identified E.coli were producing ESBl. Therefore, we recommend to use molecular methods in such researches.

Full-Text [PDF 264 kb]   (161146 Downloads)    
Type of Study: Original Research Article |
Received: 2011/11/17 | Accepted: 2014/06/22 | Published: 2014/06/22

References
1. Bradford PA. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev. 2001; 14: 933-51. [DOI:10.1128/CMR.14.4.933-951.2001] [PMID] [PMCID]
2. Falagas ME, Karageorgopoulos DE. Extended-spectrum b-lactamase-producing Organisms. J Hospital Infection. 2009.73: 345-54. [DOI:10.1016/j.jhin.2009.02.021] [PMID]
3. Emery CL, Weymouth LA. Detection and clinical significance of extended- spectrum β-lactamases in a tertiary-care medical center. J Clin Microbiol. 1997; 35: 2061-7. [DOI:10.1128/JCM.35.8.2061-2067.1997] [PMID]
4. Paterson DL, Bonomo RA. Extended-spectrum b-lactamases: a clinical update. Clin Microbiol Rev. 2005; 18: 657-86. [DOI:10.1128/CMR.18.4.657-686.2005] [PMID] [PMCID]
5. Raveh D, Yinnon AM, Broide E, Rudensky B. Susceptibilities of ESBL-producing enterobacteriaceae to ertapenem, meropenem and piperacillin-tazobactam with and without clavulanic acid. Chemotherapy. 2007; 53: 185-9. [DOI:10.1159/000100516] [PMID]
6. Matthew M. Plasmid-mediated b-lactamase of gram-negative bacteria: properties and distribution. J Antimicrob Chemother. 1979; 5: 349-58. [DOI:10.1093/jac/5.4.349] [PMID]
7. Hanna E, Sidjabat, David L, et al. Molecular epidemiology of CTX-M-producing Escherichia coli isolates at a tertiary medical center in western Pennsylvania. Antimicrob Agents Chemother. 2009; 53: 4733-39. [DOI:10.1128/AAC.00533-09] [PMID] [PMCID]
8. Khalaf NG, Eletreby MM, Hanson ND. Characterization of CTX-M ESBLs in Enterobacter cloacae, Escherichia coli and Klebsiella pneumoniae clinical isolates from Cairo, Egypt. BMC Infectious Diseases. 2009; 4: 84. [DOI:10.1186/1471-2334-9-84] [PMID] [PMCID]
9. Moubareck C, Daoud Z, Hakime NI, et al. Countrywide spread of community- and hospital-acquired extended-spectrum beta-lactamase (CTX-M-15)-producing Enterobacteriaceae in Lebanon. J Clin Microbiol. 2005; 43: 3309-13. [DOI:10.1128/JCM.43.7.3309-3313.2005] [PMID] [PMCID]
10. Bouchillon SK, Johnson BM, Hoban DJ, et al. Determining incidence of extended spectrum beta-lactamase producing enterobacteriaceae, vancomycin-resistant enterococcus faecium and methicillin-resistant staphylococcus aureus in 38 centres from 17 countries: the PEARLS study 2001-2002. Int J Antimicrob Agents. 2004; 24: 119-24. [DOI:10.1016/j.ijantimicag.2004.01.010] [PMID]
11. Poirel L, Decousser JW, Nordmann P. Insertion sequence ISEcp1B is involved in expression and mobilization of a bla(CTX-M) beta-lactamase gene. Antimicrob Agents Chemother. 2003, 47: 2938-45. [DOI:10.1128/AAC.47.9.2938-2945.2003] [PMID] [PMCID]
12. Bonnet R. Growing group of extended spectrum b-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother. 2004; 48: 1-14. [DOI:10.1128/AAC.48.1.1-14.2004] [PMID] [PMCID]
13. Mirzaee M, Pourmand MR, Chitsaz M, Mansouri S. Antibiotic resistance to third generation cephalosporins due to CTX-M-Type Extended-Spectrum β-Lactamases in clinical isolates of Escherichia coli. Iranian J Publ Health. 2009; 1: 10-7.
14. Bameri Z, Chitsaz M, Owlia P. Detection of CTX-M- lactamases in isolated klebsiella pneumoniae. Iran J Pathol. 2010; (5); 137-42.
15. Nasehi L, Shahcheraghi F, Sadat Nikbin V, Nematzadeh S. PER, CTX-M, TEM and SHV beta-lactamases in clinical isolates of klebsiellapneumoniae isolated from Tehran, Iran. Iran J Basic Medi Scie. 2010; 13: 111-8.
16. Soltan Dalal MM, Mobasseri G, Fallah Mehrabadi J, et al. Detection of CTX-M-1 beta lactamase gene in escherichia coli isolated from clinicall samples by using polymerase chain reaction (PCR) method. Tehran Uni Med J. 2011; 69: 16-21.
17. Petroni A, Corso A, Melano R, et al. Plasmidic extended-spectrum β-lactamases in Vibrio cholerae O1 ELTor isolates in Argentina. Antimicrob Agents Chemother. 2002; 46(5):1462-8. [DOI:10.1128/AAC.46.5.1462-1468.2002] [PMID] [PMCID]
18. Paterson DL. Resistance in gram-negative bacteria: enterobacteriaceae. Am J Med. 2006; 119: S20-8. [DOI:10.1016/j.amjmed.2006.03.013] [PMID]
19. Soltan Dallal MM, Molla Aghamirzaei H, Fallah Mehrabadi J. Molecular detection of TEM and AmpC( Dha, mox) broad spectrum β-lactamase in clinical isolates of Escherichia coli: PCR method. Tehran Uni Med J. 2010; 68: 872-7.
20. AL-Jasser MA. Extended-spectrum beta-lactamases (ESBLs): a global problem. Kuwait Med J. 2006; 38: 171-85.
21. Canton R, Coque TM. The CTX-M b-lactamase pandemic. Curr Opin Microbiol. 2006; 9: 466-75. [DOI:10.1016/j.mib.2006.08.011] [PMID]
22. Goyal A, Prasad K.N, Prasad A, Gupta S, Ghoshal U, Ayyagari A. Extended spectrum β-lactamases in Escherichia coli & Klebsiella pneumoniae & associated risk factors. Indian J Med Res. 2009; 129: 695-700.
23. Mugnaioli C, Luzzaro F, De Luca F, et al. CTX-M-type extended-spectrum β-lactamases in Italy: molecular epidemiology of an emerging countrywide problem. Antimicrob Agents Chemother. 2006; 50: 2700-6. [DOI:10.1128/AAC.00068-06] [PMID] [PMCID]
24. Petroni A, Corso A, Melano R, et al. Plasmidic extended-spectrum β-lactamases in Vibrio cholerae O1 ELTor isolates in Argentina. Antimicrob Agents Chemother. 2002; 46: 1462-8. [DOI:10.1128/AAC.46.5.1462-1468.2002] [PMID] [PMCID]
25. Yagi T, Kurokawa H, Shibata N, Shibayama K, Arakawa Y. A preliminary survey of extended-spectrum β-lactamases (ESBLs) in clinical isolates of Klebsiella pneumoniae and Escherichia coli in Japan. FEMS Microbiol Lett. 2000; 184: 53-6. [DOI:10.1111/j.1574-6968.2000.tb08989.x] [PMID]
26. Mirsalehian A, Akbari-Nakhjavani F, Peymani A, Kazemi B, Jabal Ameli F, Mirafshar SM. Prevalence of extended spectrum β-Lactamase-producing enterobacteriaceae by phenotypic and genotypic methods in intensive care units in Tehran, Iran. Daru. 2008; 16: 169-73.
27. Shahcheraghi F, Nasiri S and Naviri H. Evalouation of presence the bla-SHV and bla-TEM β-Lactamase genes in clinical isolates resistant Escherichia coli to antibiotics from Tehran hospital. Iran J Med Microbiol. 1386; 1: 1-8.
28. Soltan Dallal MM, Sabbaghi A, Fallah Mehrabadi J, et al. Evaluation of presence the bla-SHV and bla-AmpC (CITM, FOX) β-lactamase genes in clinical isolates of Escherichia coli. J of Med Council. 2010. 28: 269-76.

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 CC BY-NC 4.0 | Journal of Advances in Medical and Biomedical Research

Designed & Developed by : Yektaweb